Likely Impact of Net Price Referencing on European Markets Patel P, Ladrón de Guevara P Alliance Life Sciences Consulting Group, London, UK OBJECTIVES With the introduction of new pricing measures in countries such as Germany, the visibility of net pharmaceutical product prices (prices with a mandatory rebate) could soon become a requirement. Three European markets that currently employ rebates are Germany, Spain and Italy. The objective of this study is to map out likely consequences of International Price Referencing (IRP) using net prices on three products; Avastin, Caprelsa and Vidaza. METHODS Using data from PRICENTRIC, we collected net and list ex-factory prices for Avastin, Caprelsa and Vidaza across EU-28. Countries that do not use formal IRP as a price setting mechanism were excluded from the analysis, countries that consider price reviews were included. Projected prices were calculated using country IRP rules and exchange rates from the European Central Bank. The current approved prices were compared to the likely projected prices. The analysis investigated two key areas: 1. Countries impacted 2. Potential price impact. RESULTS Figure 1 shows the current prices for the 3 products. Figure 2 illustrates the countries impacted by the change and likely price points. One of the first countries affected would be Netherlands (Netherlands reviews prices every 6 months), followed closely by Switzerland and Ireland. The potential impact could range from price reductions of 9.69% for Vidaza in Ireland to 30.77% for Avastin in Switzerland. CONCLUSIONS The trend for net price referencing has already been adopted by Greece since February 2014 where Greece moved from referencing the Italian list price to the net price. The concern for industry if this were to become the norm for other markets and if net prices were to become publically visible, substantial price reductions could be on the horizon.